Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
42.33
+0.29 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
26
27
Next >
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
February 10, 2023
From
Genentech
Via
Business Wire
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
February 07, 2023
Via
Benzinga
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
February 07, 2023
From
Genentech
Via
Business Wire
Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant
January 26, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
February 02, 2023
Via
Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
January 19, 2023
Via
Benzinga
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
January 19, 2023
From
Genentech
Via
Business Wire
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
January 17, 2023
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...
Via
Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
January 12, 2023
Via
Benzinga
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
January 09, 2023
Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news.
Via
Investor's Business Daily
Twitter Hackers Stole More Than 200M Emails, Delta Air Lines To Offer Free Wi-Fi, Bed Bath & Beyond's Bankruptcy Coming Sooner Than Expected: Top Stories Today
January 06, 2023
Benzinga
Via
Benzinga
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review
January 06, 2023
Via
Benzinga
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
January 06, 2023
From
Genentech
Via
Business Wire
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
January 05, 2023
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall.
Via
Investor's Business Daily
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
January 02, 2023
Which of these companies is better able to replace declining COVID-19-related sales?
Via
The Motley Fool
Big Health Care Stocks to Watch in the New Year
December 29, 2022
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.
Via
MarketBeat
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
December 28, 2022
Investors are closely watching two key spaces that could spark Lilly stock.
Via
Investor's Business Daily
Roche's Follicular Lymphoma Therapy Scores FDA Approval
December 23, 2022
Via
Benzinga
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
December 22, 2022
From
Genentech
Via
Business Wire
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
December 22, 2022
Via
Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
December 21, 2022
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...
Via
Talk Markets
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
December 21, 2022
From
Genentech
Via
Business Wire
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
December 20, 2022
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock.
Via
InvestorPlace
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
December 20, 2022
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche.
Via
Investor's Business Daily
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
December 19, 2022
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum
Via
MarketBeat
OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes
December 14, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ)...
Via
TheNewswire.com
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
December 13, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022.
Via
Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
December 12, 2022
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.